Zentalis Pharmaceuticals (ZNTL) Depreciation & Amortization (CF) (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Depreciation & Amortization (CF) of $151000.0 for Q1 2026, down 42.37% year-over-year from $262000.0 in Q1 2025, and up 27.97% quarter-over-quarter from $118000.0 in Q4 2025.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $151000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 42.37% year-over-year to $151000.0; the TTM figure through Mar 2026 stood at $589000.0 (down 52.0% YoY), while the FY2025 annual figure was $700000.0, down 45.69% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $151000.0, up from $118000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $375000.0 in Q3 2022, with the low at $118000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $321000.0 (2024), against an average of $285823.5.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 335.44% in 2022, then sank 62.78% in 2025.
- Zentalis Pharmaceuticals' Depreciation & Amortization (CF) stood at $300000.0 in 2022, then changed by 0.0% to $300000.0 in 2023, then rose by 5.67% to $317000.0 in 2024, then tumbled by 62.78% to $118000.0 in 2025, then climbed by 27.97% to $151000.0 in 2026.
- Business Quant data shows ZNTL's Depreciation & Amortization (CF) at $151000.0 in Q1 2026, $118000.0 in Q4 2025, and $160000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | 152,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 152,000.00 |
| Mar 31, 2026 | 151,000.00 |
| Dec 31, 2025 | 157,000.00 |
| Sep 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Dec 31, 2024 | 328,000.00 |
| Sep 30, 2024 | 321,000.00 |
| Jun 30, 2024 | 327,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Sep 30, 2023 | 348,000.00 |
| Jun 30, 2023 | 344,000.00 |
| Mar 31, 2023 | 360,000.00 |
| Dec 31, 2022 | 326,000.00 |
| Sep 30, 2022 | 375,000.00 |
| Jun 30, 2022 | 348,000.00 |
| Mar 31, 2022 | 344,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 137,000.00 |